Moreover, the successfully completed Phase 1 of the clinical trial of SLE treatment by CD40L (http://www.biogenidec.com/research_product_pipeline.aspx?ID=5778) provides evidence of the important role of the CD40–CD40L interaction in the pathogenesis of SLE. The gene discussed is CD40LG; the disease is systemic lupus erythematosus.